Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.

Journal of viral hepatitis - 1 Nov 2014

Ayres A, Yuen L, Jackson K M, Manoharan S, Glass A, Maley M, Yoo W, Hong S P, Kim S-O, Luciani F, Bowden D S, Bayliss J, Levy M T, Locarnini S A

Abstract excerpt

This study sought to assess the antiviral efficacy of lamivudine (LMV) administered during third trimester to reduce maternal viraemia and to identify the emergence of LMV resistance. A prospective observational analysis was performed on 26 mothers with high viral load (>10⁷ IU/mL). Twenty-one wo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood
Share to Drug Resistance, Viral
Share to Hepatitis B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Infectious Disease Transmission, Vertical

Share to Lamivudine

Share to Pregnancy Complications, Infectious

Share to Viral Load

Source

Identifiers

PMID: 24329944
DOI: 10.1111/jvh.12212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24329944-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.PMID 24329944Read ↗

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Semantic proximity Read ↗

High prevalence of pre-existing HBV polymerase mutations in pregnant women do not limit the telbivudine treatment efficacySemantic proximity Read ↗

Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.Semantic proximity Read ↗

Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factorsSemantic proximity Read ↗

HBV mutations associated with lamivudine therapy.Semantic proximity Read ↗

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.Semantic proximity Read ↗

Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.Semantic proximity Read ↗

Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.Semantic proximity Read ↗

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Semantic proximity Read ↗

Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.Semantic proximity Read ↗

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.